Oncotarget, keeping you in the know on matters oncology

There has been a long string of studies and research based on cancer and many medications which aim at reducing the impact of the killer disease. Some of the drugs which have come up include Naloxone. According to a recent report by oncortagert authors, the role of naloxone has been poorly studied, and its efficiency has been largely ignored. Nevertheless, the summary of the report indicates that naloxone helps to mainly reduce and also to prevent the progression of breast cancer without affecting angiogenesis in any way. Check Oncotarget journal at scimagojr.com


When it comes to keeping people informed about the latest research on cancer, Oncotarget is always on the frontline. For those who don’t know what it is, Oncotarget is a bio-medical journal released twice a week and focuses on matters oncology. The management of the research journal recently announced that all its scientific publications will now be available on more platforms such as PubMed Central, Scopus, BIOSIS Previews, science citation index expanded, Biological Abstracts and many others to enable more people to access the information. The publication works with high-end archives and scientific research centres to get more reliable information and also to make it available to all members of the general public including practitioners and physicians. The founder of Oncotarget wants to make the information on oncology as accessible as possible, and that is why it ensures that it releases the medical journal twice a week. Some of the subjects covered include microbiology, pathology, ageing, autophagy, chromosomes, and immunology among many other areas which cover the health of the human body most particularly on cancer.

Visit: https://oncotarget.msubmit.net/cgi-bin/main.plex

More on Oncotarget

In 2010 Mikhail Blagosklonny and Andrei Gudkov who are both well-known researchers came together and decided to share information regarding oncology to the general public by establishing the journal. They are the editors-in-chief of Oncotarget, and since then it has released more than three hundred issues. It is currently in its eighth volume, and Impact journal makes the publications. Under the leadership of the two scientists, the journal continues to make a positive difference in the world by making more people know about various aspects of the body. They are also active on social media, especially on Twitter.